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Abstract
Background
South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734
patients diagnosed in 2014. The number of diagnosed patients has increased substantially
with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all
patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-
treatment loss to follow-up) between the numbers of patients with laboratory-confirmed
RR-TB and those reported to have started second-line treatment. We aimed to assess the
impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to fol-
low-up before second-line treatment for RR-TB across South Africa.
Methods and findings
A nationwide retrospective cohort study was conducted to assess second-line treatment initia-
tion and treatment delay among laboratory-diagnosed RR-TB patients. Cohorts, including
approximately 300 sequentially diagnosed RR-TB patients per South African province, were
drawn from the years 2011 and 2013, i.e., before and after Xpert implementation. Patients with
prior laboratory RR-TB diagnoses within 6 mo and currently treated patients were excluded.
Treatment initiation was determined through data linkage with national and local treatment reg-
isters, medical record review, interviews with health care staff, and direct contact with patients
or household members. Additional laboratory data were used to track cases. National estimates
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of the percentage of patients who initiated treatment and time to treatment were weighted to
account for the sampling design.
There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts, respectively;
92% were newly diagnosed with RR-TB (no prior RR-TB diagnoses). Nationally, among the
2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53%–
57%) and 63% (95% CI 61%–65%), respectively, started treatment within 6 mo of laboratory
receipt of their diagnostic specimen (p < 0.001). However, in 2013, there was no difference
in the percentage of patients who initiated treatment at 6 mo between the 1,368 new RR-TB
patients diagnosed by Xpert (62%, 95% CI 59%–65%) and the 943 diagnosed by other
methods (64%, 95% CI 61%–67%) (p = 0.39). The median time to treatment decreased
from 44 d (interquartile range [IQR] 20–69) in 2011 to 22 d (IQR 2–43) in 2013 (p < 0.001).
In 2013, across the nine provinces, there were substantial variations in both treatment initia-
tion (range 51%–73% by 6 mo) and median time to treatment (range 15–36 d, n = 1,450),
and only 53% of the 1,448 new RR-TB patients who received treatment were recorded in
the national RR-TB register.
This retrospective study is limited by the lack of information to assess reasons for non-ini-
tiation of treatment, particularly pre-treatment mortality data. Other limitations include the
use of names and dates of birth to locate patient-level data, potentially resulting in missed
treatment initiation among some patients.
Conclusions
In 2013, there was a large treatment gap for RR-TB in South Africa that varied significantly
across provinces. Xpert implementation, while reducing treatment delay, had not contrib-
uted substantially to reducing the treatment gap in 2013. However, given improved case
detection with Xpert, a larger proportion of RR-TB patients overall have received treatment,
with reduced delays. Nonetheless, strategies to further improve linkage to treatment for all
diagnosed RR-TB patients are urgently required.
Author summary
Why was this study done?
• Tuberculosis (TB) that is resistant to rifampicin, one of the most important first-line TB
drugs, is more difficult to treat than drug-susceptible TB and requires treatment with
second-line TB drugs. South Africa diagnoses close to 20,000 patients with rifampicin-
resistant TB each year, but routine data suggest that a large proportion of these patients
do not receive adequate treatment (treatment gap).
• South Africa has implemented the Xpert MTB/RIF test (a rapid test for TB and rifampi-
cin resistance) for all individuals being investigated for TB. Prior to this, only a subset of
TB patients received drug susceptibility testing, and the diagnosis of drug-resistant TB
was often delayed, resulting in delayed treatment initiation.
• In South Africa, the number of diagnosed rifampicin-resistant TB patients is derived
from laboratory data, while the number of patients who receive second-line treatment is
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derived from a separate treatment register. As both of these data sources provide aggre-
gate numbers that are not linked, we do not have an accurate estimate of the proportion
of patients who receive second-line treatment.
• Use of Xpert was expected to both increase case detection for rifampicin-resistant TB
and reduce the delay to second-line treatment initiation, thereby increasing the propor-
tion of diagnosed patients who receive treatment.
What did the researchers do and find?
• A retrospective cohort study was conducted to quantify the proportion of diagnosed
patients who received second-line treatment and the delay to treatment.
• Two cohorts of approximately 2,500 patients each were identified: the first in 2011 prior
to Xpert implementation and the second in 2013 after Xpert implementation.
• While treatment initiation increased from 55% in 2011 to 63% in 2013, the percentage
of patients starting second-line treatment was low overall and varied considerably across
the nine provinces of South Africa.
• Xpert contributed to a reduction in treatment delay from a median of 44 days in 2011 to
22 days in 2013, but did not significantly improve the proportion receiving treatment.
What do these findings mean?
• Use of Xpert contributes to reduced delays to treatment initiation but does not reduce
the treatment gap. However, given improved case detection, a larger proportion of the
total population of individuals with rifampicin-resistant TB will receive treatment.
• Further strategies to improve linkage to treatment for all patients diagnosed with rifam-
picin-resistant TB are required.
Introduction
The global epidemic of drug-resistant tuberculosis (DR-TB) is largely undiagnosed and untreated.
In 2014, barely 23% of the estimated incident cases of multidrug-resistant tuberculosis or rifampi-
cin-resistant tuberculosis (RR-TB) were initiated on appropriate second-line anti-tuberculosis
therapy [1]. The remainder contribute to ongoing transmission [2] and suffer high mortality. At a
global level, the major bottleneck in the cascade from diagnosis through to cure is access to drug
susceptibility testing (DST); only 12% of previously untreated tuberculosis (TB) patients are
reported to receive any DST [1]. Subsequent gaps in the cascade occur due to poor access to treat-
ment and poor outcomes with currently available second-line treatment [1].
The rollout of the Xpert MTB/RIF test has increased access to DST in several high-burden
settings, including South Africa. Xpert provides rapid diagnosis of RR-TB, leading to results
being available to clinicians in days rather than weeks or months, as with culture-based methods
[3]. Earlier diagnosis should allow earlier initiation of second-line treatment and potentially
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reduce the proportion of patients who never start treatment (pre-treatment loss to follow-up),
potentially improving patient outcomes and reducing the risk of transmission [4,5]. Diagnosing
a greater proportion of the estimated community burden of RR-TB, initiating second-line treat-
ment for a larger proportion of those who are diagnosed, and subsequently providing successful
treatment are all important elements for improving the DR-TB care cascade.
South Africa has a large burden of RR-TB; in 2014, 18,734 RR-TB cases were notified to the
World Health Organization (WHO), considerably more than the number of incident RR-TB
cases estimated by WHO to occur [1]. This represents a substantial increase over previous years,
most likely reflecting improved detection of RR-TB with Xpert; however, access to treatment has
remained a challenge. In 2011, prior to Xpert rollout, only 5,643 patients were reported to have
started second-line treatment, representing just 56% of the 10,085 patients identified by the
National Health Laboratory Service (NHLS) and notified to WHO that year [1]. In 2013, when
the rollout of Xpert was largely complete, 10,663 patients were reported to be treated, 72% of the
14,881 notified patients (revised notified figure, personal communication, Nazir Ismael, 2016)
[1]. Given the lack of unique patient identifiers, notifications based on laboratory data are likely
to include duplicate results from the same patient and may therefore overestimate RR-TB bur-
den. Similarly, the number of treated RR-TB patients in South Africa is derived from a national
electronic DR-TB treatment register (EDRWeb), for which data entry is centralised in specialised
TB treatment centres in each province, potentially missing patients who receive treatment in
decentralised treatment sites. As a result, the treatment gap may be substantially different from
that calculated using these routine data sources.
In this study we aimed to determine the proportion of patients with laboratory-diagnosed
RR-TB who started second-line treatment and the time to treatment start, comparing cohorts
drawn from 2011 (before Xpert availability) and 2013 (after widespread Xpert availability). We
further aimed to assess patient-level, geographic, and programmatic factors, such as the decen-
tralisation of RR-TB treatment, associated with second-line treatment initiation.
Methods
Ethics approval for the study was obtained from the University of Cape Town and the London
School of Hygiene & Tropical Medicine. Programmatic approvals were obtained from the
South African National Department of Health, provincial departments of health, metropolitan
health departments, and relevant health districts and facilities. Approvals were also obtained to
access relevant data from three large private laboratories operating in South Africa and the
National Department of Correctional Services.
Study design
The study was a retrospective observational cohort study across all nine South African prov-
inces. Two retrospective cohorts comprised approximately 300 RR-TB patients from each
province, sampled sequentially from January 1 onwards in 2011 and 2013. The primary out-
come was the proportion of individuals who initiated second-line treatment within 6 mo from
the date the NHLS laboratory received the specimen on which the diagnosis of RR-TB was
based. Six months was considered as the maximum time to consider treatment initiation
within the same diagnostic episode.
Participants
Patients with RR-TB were included regardless of previous TB treatment history, although in
order to include predominantly newly diagnosed RR-TB patients, those with a previous
RR-TB diagnosis within the 6 mo prior to the cohort inclusion period were excluded, as were
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those currently receiving second-line treatment. Inclusion was based on any RR-TB result,
regardless of laboratory method. Patients were retrospectively followed up using a range of
data sources (see below) to determine and verify the primary outcome of second-line treat-
ment initiation. Data collection was conducted from 13 January 2014 through 24 April 2015,
allowing a minimum of 6 mo follow-up time for both cohorts. The study was retrospective so
that the conduct of the study would not influence treatment initiation within the 6-mo time
period of interest through active follow-up of patients at health facilities.
Time to treatment (days) was determined as the difference between the date the diagnostic
specimen (specimen from which RR-TB was diagnosed) was received in the NHLS laboratory
and the date second-line treatment was initiated. Specimen receipt in the laboratory was used
instead of the specimen collection date due to the unreliability of collection data in this field. A
treatment regimen was considered to be second-line if it contained at least two second-line
agents, including at least one of a fluoroquinolone or a second-line injectable agent. Patients
for whom no previous RR-TB diagnosis could be found were defined as newly diagnosed with
RR-TB, while those with prior RR-TB diagnoses (beyond the 6 mo immediately before the
inclusion period) were defined as previously diagnosed with RR-TB. Previously diagnosed
RR-TB patients were further classified according to whether they had previously received sec-
ond-line treatment.
Data sources
Cohorts were established based on routine laboratory data from the NHLS in South Africa. All
public-sector TB laboratory testing is done by the NHLS, and test details are captured on a labo-
ratory information system. Only public-sector data were used as these were expected to cover
the vast majority of diagnosed cases in South Africa; most patients diagnosed in the private sec-
tor are referred to the public sector for treatment and would therefore appear in the public sector
records. NHLS data are held in a central repository, and duplicate patients are identified initially
by an algorithm that matches according to health care facility medical record numbers. After
data extraction of all RR-TB diagnoses in the relevant time periods and 6 mo prior, potential fur-
ther duplicates were identified using in-house software based on approximate text matching.
Potential matches were identified based on first name and surname separately and in combina-
tion. Potential matches with exactly matching dates of birth were confirmed automatically, while
remaining matches were reviewed manually by at least two researchers, with a third reviewer if
the first two reached different conclusions. Overall, 19% of>68,000 potential matches identified
were confirmed.
Determination of second-line treatment initiation followed a stepwise process (Fig 1). First,
cohort patients were matched using combinations of names, date of birth, and location to the
two main electronic TB treatment registers in South Africa; the DR-TB treatment register
(EDRWeb, from the South African National Department of Health, United States President’s
Emergency Plan for AIDS Relief, and US Centers for Disease Control and Prevention Global
AIDS Program) and the first-line TB treatment register (ETR.Net). Data in these registers are
collated centrally by the National Department of Health. All potential matches were verified
manually. In addition, all patients, including those already matched to the electronic registers,
were also tracked through paper-based treatment registers at all major treatment centres (hospi-
tals and large decentralised treatment sites) in each province. Second, patients without verified
second-line treatment start dates were then traced individually, starting from the diagnosing
health care facility through referral and treatment facilities, to determine potential treatment
initiation. This process included review of individual medical records where available and direct
follow-up with health facility staff. Third, remaining patients without second-line treatment
The drug-resistant TB treatment gap in South Africa
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start dates were then tracked through all NHLS laboratory records (any laboratory test) nation-
ally to determine care seeking at any other facility in any province. Patient names were also
linked to laboratory results in both the private sector (three major private laboratories in South
Africa) and from correctional services in each province in order to further determine potential
places and dates of second-line treatment initiation. Finally, attempts were made to directly
contact remaining patients without second-line treatment initiation data, or their family mem-
bers, through telephone and address details sourced from medical records in the diagnosing
health care facility. Overall,>950 separate health care facilities were visited at least once through
the study.
Previous and subsequent NHLS laboratory records were identified for each patient to deter-
mine previous RR-TB diagnoses and previous or current second-line treatment. Patients were
deemed to have been followed up if any record of the patient beyond the initial laboratory
Fig 1. Schematic diagram illustrating the stepwise process for follow-up of cohort patients. EDR, EDR.
Net; NHLS, National Health Laboratory Service; SL, second-line.
doi:10.1371/journal.pmed.1002238.g001
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report could be found at a health facility or in laboratory records. Given that lack of follow-up
could also represent a single presentation at a health facility, all eligible patients were included
in analyses, regardless of follow-up. In addition to data from the diagnostic test and the pri-
mary outcome of second-line treatment initiation, other data variables including age, sex, HIV
status, second-line treatment facility, and date of death (when available) were collected.
Sample size determination
Both the burden of RR-TB and population size vary significantly across the nine South African
provinces. In addition, given varying strategies for RR-TB management, significant variations
in both the percentage of patients who initiate treatment and the time to treatment are expected
across provinces. In order to inform policy, valid provincial estimates of the percentage of diag-
nosed patients initiating second-line treatment and a comparison between 2011 and 2013 for
this percentage were required. The sample size for each province was therefore based on an esti-
mated 50% treatment initiation in 2011, with a 15% change in 2013 as the minimum significant
difference to detect. The resulting sample size required was 240 per cohort at 90% power. This
was increased to 300 to allow for duplicate patients and patients found to be ineligible during
follow-up. This resulted in an overall sample size of approximately 5,000, which was considered
feasible given the logistics of following up large patient cohorts across a large number of health
facilities and through routine data sources.
Statistical methods
Because sampling in each province did not reflect variation in the burden of RR-TB across the
nine provinces, post-stratification sampling weights were applied to derive national-level estimates
of the percentage of patients who initiated treatment and median time to treatment. Weights were
calculated based on the time needed to reach the final sample size of RR-TB patients in each prov-
ince as a proxy for the burden of diagnosed RR-TB in each province. An estimate of the overall
national burden was calculated by multiplying the final sample size for each province by 1 y/[time
taken to enrol the sample from each province]. The population weight for the ith province was
then calculated as the percentage contribution from province i to the national burden divided by
the percentage contribution of province i to the sample.
Time-to-event analyses were conducted using Cox regression and were not censored for
loss to follow-up or mortality. Data on mortality were not available for the majority of patients
who did not initiate second-line treatment. Among the patients who did not initiate treatment,
a proportion were found through records to have been still “in care” across the 6-mo period of
potential treatment initiation. However, the majority were not identified through any records
in any health facility for most of the 6-mo period. Differences in proportions were assessed
with Pearson chi-squared analyses, while medians were compared using the Mann–Whitney
U test. Data were analysed with SPSS Statistics (IBM, version 23). Data were deposited in the
Dryad Digital Repository [6].
Results
Description of cohorts
The initial 2011 pre-Xpert cohort included 2,703 patients, while 2,743 patients were included
in the 2013 post-Xpert cohort. During data collection and verification, 410 (7.5%) patients
were excluded as they were found to have had a previous RR-TB diagnosis in the 6 mo prior to
the cohort period or were determined to have been receiving second-line treatment at the time
The drug-resistant TB treatment gap in South Africa
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of the inclusion RR-TB laboratory result (Fig 2). Of the remaining eligible patients, 98% (2,463
in 2011 and 2,486 in 2013) were defined as followed up through relevant data sources.
The 2011 and 2013 cohorts were similar in terms of age, sex, and HIV status (Table 1). HIV
status was known for 82% (2,060/2,508) of patients in the 2011 cohort and 87% (2,189/2,528)
in the 2013 cohort, with 63% (1,577) and 66% (1,663) found to be HIV positive, respectively.
Among the two cohorts, 93% (2,340) and 91% (2,311) of patients in 2011 and 2013, respec-
tively, were determined through follow-up to be newly diagnosed with RR-TB; the remainder
had records of previous diagnoses (not in the previous 6 mo), both with and without record of
any prior second-line treatment (Fig 2).
Among newly diagnosed RR-TB patients in the 2013 cohort, HIV prevalence ranged from
54% to 75% across the nine provinces (Table 2). The majority of new RR-TB patients in both
cohorts and across provinces submitted specimens for diagnosis in primary care facilities,
Fig 2. Flow diagram showing initial inclusion, exclusions, and determination of newly and previously
diagnosed rifampicin-resistant tuberculosis. RR-TB, rifampicin-resistant tuberculosis; SL, second-line.
doi:10.1371/journal.pmed.1002238.g002
The drug-resistant TB treatment gap in South Africa
PLOS Medicine | DOI:10.1371/journal.pmed.1002238 February 21, 2017 8 / 19
followed by secondary- and tertiary-level hospitals and a smaller percentage from specialised
TB hospitals (Table 1).
RR-TB diagnosis
The diagnostic test that first detected rifampicin resistance among new RR-TB patients varied
between the two cohorts. There was a small percentage of patients in the 2011 cohort diag-
nosed using Xpert; these were primarily from pilot implementation or research sites. Despite
complete rollout of Xpert testing, only 59% (1,368/2,311) of new RR-TB patients from the
2013 cohort were diagnosed initially with Xpert. The remainder were diagnosed primarily
with a line probe assay (Hain Lifescience, Germany), either performed directly on a smear
specimen or after a positive TB culture (Table 1). To assess if diagnosis with a test other than
Xpert was due to non-availability of Xpert, we determined the date that Xpert was first used
routinely in each district. Among the 943 patients in the 2013 cohort not diagnosed with
Xpert, 42 (5%) were diagnosed from specimens sent to the laboratory before Xpert was used
routinely.
Diagnosis with Xpert varied considerably across provinces, ranging from 33% to 83% in
2013 (Table 2). Among newly diagnosed RR-TB patients in the 2013 cohort, the proportion of
Table 1. Demographic and clinical data by cohort.
Characteristic 2011 cohort 2013 cohort
Total eligible 2,508 2,528
Female 1,181 (47%) 1,192 (47%)
Age (median, interquartile range) 35, 27–43 35, 27–43
Missing age 14 8
HIV status
Negative 483 (19%) 526 (21%)
Positive 1,577 (63%) 1,663 (66%)
Unknown 448 (18%) 339 (13%)
Smear status
Negative 853 (34%) 577 (23%)
Positive 1,314 (52%) 913 (36%)
Missing 341 (14%) 1,038 (41%)
Newly diagnosed RR-TB 2,340 (93%) 2,311 (91%)
Laboratory test that first detected rifampicin resistance (new RR-TB
only)
Xpert 88 (4%) 1,368 (59%)
Line probe assay 1,694 (72%) 801 (35%)
Phenotypic DST 558 (24%) 142 (6%)
Diagnosing facility (new RR-TB only)
Primary health care 1,539 (66%) 1,564 (68%)
Secondary hospital 536 (23%) 534 (23%)
Tuberculosis hospital 152 (7%) 106 (5%)
Tertiary hospital 90 (4%) 85 (4%)
Other 23 (1%) 22 (1%)
Data are given as n (percent) unless otherwise indicated. Data on diagnostic test that first detected
rifampicin resistance and facility where specimen was collected are given for newly diagnosed RR-TB
patients only.
DST, drug susceptibility testing; RR-TB, rifampicin-resistant tuberculosis.
doi:10.1371/journal.pmed.1002238.t001
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HIV-positive and HIV-negative patients who were diagnosed initially with Xpert was not dif-
ferent, 60% (916/1,518) and 56% (258/460), respectively (p = 0.10).
The median time between the date the NHLS laboratory received the diagnostic specimen
and the date the result was reviewed by the laboratory, used as a proxy for laboratory diagnos-
tic time, reduced from 38 d (interquartile range [IQR] 10–67) in 2011 to 2 d (IQR 0–15) in
2013 among new RR-TB patients (p< 0.001). In 2013, the laboratory diagnostic time was 1 d
(IQR 0–1) for new patients diagnosed with Xpert, 29 d (IQR 13–46) for patients diagnosed
with line probe assay (including both direct testing on specimens and after culture), and 47 d
(IQR 37–57) for patients diagnosed with phenotypic DST.
Second-line treatment initiation
Second-line treatment initiation within 6 mo of the diagnostic specimen increased from 55%
(95% CI 53%–57%) among 2,340 newly diagnosed RR-TB patients in 2011 to 63% (95% CI
61%–65%) of 2,311 patients in 2013 (p< 0.001). The median time to treatment among new
RR-TB patients starting treatment within 6 mo was reduced by half from 2011 to 2013,
Table 2. New rifampicin-resistant tuberculosis patients and their HIV status, diagnosing facility, and Xpert diagnosis across the nine South Afri-
can provinces (2013 cohort).
Characteristic Province
1 2 3 4 5 6 7 8 9
N (RR-TB diagnoses) 287 290 283 272 279 261 286 284 286
New RR-TB diagnosis 266 (93%) 268 (92%) 264 (93%) 256 (94%) 261 (94%) 231 (89%) 267 (93%) 259 (91%) 239 (84%)
New RR-TB patients
HIV negative 64 (24%) 49 (18%) 19 (7%) 40 (16%) 42 (16%) 36 (16%) 37 (14%) 78 (30%) 95 (40%)
HIV positive 165 (62%) 182 (68%) 186 (71%) 193 (75%) 176 (67%) 165 (71%) 175 (66%) 148 (57%) 128 (54%)
HIV status unknown 37 (14%) 37 (14%) 59 (22%) 23 (9%) 43 (17%) 3 (13%) 55 (21%) 33 (13%) 16 (7%)
Diagnostic specimen from PHC 188 (71%) 206 (77%) 145 (55%) 159 (62%) 157 (60%) 136 (59%) 190 (71%) 206 (80%) 177 (74%)
Xpert diagnosis 158 (59%) 189 (71%) 153 (58%) 145 (57%) 216 (83%) 76 (33%) 164 (61%) 169 (65%) 98 (41%)
Data are given as n (percent).
PHC, primary health care; RR-TB, rifampicin-resistant tuberculosis.
doi:10.1371/journal.pmed.1002238.t002
Fig 3. Time to treatment initiation from diagnostic specimen for new rifampicin-resistant tuberculosis
patients from the 2011 and 2013 cohorts (p < 0.001). Solid line: 2011 cohort; dashed line: 2013 cohort.
doi:10.1371/journal.pmed.1002238.g003
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decreasing from 44 d (IQR 20–69) to 22 d (IQR 2–43) (p< 0.001) (censored at 6 mo). In 2013,
only 10% (95% CI 8%–11%) of 2,311 new RR-TB patients had initiated treatment by the
national target of 5 d from diagnosis [7]. Fig 3 shows the difference in time to treatment initia-
tion over 6 mo for the 2011 and 2013 cohorts (p< 0.001), and Fig 4 shows the distribution of
time to treatment for each cohort (data in both figures not weighted for sampling method).
Across both cohorts, 4% of patients not diagnosed with Xpert (2,252 in 2011 and 943 in 2013)
were reported as starting treatment on the same day as the diagnostic specimen was received
in the laboratory. These patients were primarily diagnosed through specialist hospitals, sug-
gesting empiric treatment initiation based on high suspicion of RR-TB. Overall, across both
cohorts, 2% of patients who initiated treatment within 6 mo did so in a different province to
that in which they were diagnosed.
In the 2013 cohort, there was no difference in the proportion of new RR-TB patients initiat-
ing treatment within 6 mo among those diagnosed with Xpert (n = 1,368) compared to those
diagnosed by other methods (n = 943), 64% (95% CI 61%–67%) and 62% (95% CI 59%–65%),
respectively (p = 0.39). However, the median time to treatment among these patients was
reduced: 15 d (IQR 1–29) for patients diagnosed with Xpert compared to 32 d (IQR 7–57) for
patients diagnosed by other methods (p< 0.001; Fig 5).
There were significant differences in both the proportion of new RR-TB patients initiating
treatment and the median time to treatment across the nine South African provinces in 2013
(Table 3). Seven provinces showed significantly increased treatment initiation proportions
between 2011 and 2013, while the median time to treatment decreased significantly across all
nine provinces (Table 3).
In 2011, 62% the new RR-TB patients started second-line treatment (n = 1,182) at tertiary
level or specialist TB hospitals. This proportion dropped significantly in 2013 to 56% (n = 1,448)
but remained the most common type of facility for initiating second-line treatment (Table 3). Pri-
mary health care facilities were responsible for treatment initiation in 23% and 19% of patients in
2011 and 2013, respectively, but this proportion varied significantly across provinces, ranging
from 4% to 66% in 2013 (Table 3). Among new RR-TB patients found to have initiated second-
line treatment, only 62% and 53% in 2011 and 2013, respectively, were recorded in the national
electronic DR-TB treatment register. This proportion decreased significantly between 2011 and
2013 in three provinces and was<50% in five provinces in 2013 (Table 3).
Fig 4. Distribution of time to treatment by cohort.
doi:10.1371/journal.pmed.1002238.g004
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Previously diagnosed rifampicin-resistant tuberculosis patients
Overall, 8% (385/5,036) of patients, from both cohorts, were found to have a prior diagnosis of
RR-TB. Among those for whom no previous second-line treatment could be identified, the
time between the first recorded RR-TB diagnosis and the diagnostic result for which they were
included in the cohort was a median of 19 mo (Table 4). Treatment initiation (for the current
episode) was higher among these patients compared to those with records of prior treatment,
76% and 9%, respectively, with no significant difference in median time to treatment
(Table 4).
Fig 5. Time to treatment initiation from diagnostic specimen for new rifampicin-resistant tuberculosis
patients in the 2013 cohort diagnosed with Xpert compared to other methods (p < 0.001). Solid line:
diagnosed with Xpert; dashed line: diagnosed by other method.
doi:10.1371/journal.pmed.1002238.g005
Table 3. Percentage of patients who initiated treatment, time to treatment, site of treatment initiation, and recording in national drug-resistant
tuberculosis register by cohort and province (new rifampicin-resistant tuberculosis patients).
Province SL treatment start within 6 mo, N
(percent, 95% CI)
Median time
to SL
treatment
(days)
Started on SL treatment
in PHC, N (percent)
Started on SL treatment
in tertiary/TB hospital,
N (percent)
Recorded in national
DR-TB register, N
(percent)
2011 2013 2011 2013 2011 2013 2011 2013 2011 2013
1 167 (62%, 56–68) 193 (73%*, 67–78) 34 22* 7 (4%) 13 (7%) 158 (95%) 164 (85%*) 117 (70%) 139 (72%)
2 128 (48%, 42–54) 176 (66%*, 58–74) 65 18* 72 (56%) 87 (49%) 5 (4%) 10 (6%) 68 (53%) 91 (52%)
3 135 (51%, 45–57) 134 (51%, 45–56) 48 26* 13 (10%) 14 (10%) 110 (82%) 88 (66%*) 61 (45%) 36 (27%*)
4 107 (48%, 41–54) 158 (62%*, 58–65) 68 21* 9 (8%) 10 (6%) 59 (55%) 104 (66%) 74 (69%) 78 (49%*)
5 121 (46%, 39–52) 144 (55%*, 46–65) 47 33* 1 (1%) 6 (4%) 117 (97%) 128 (89%*) 44 (36%) 30 (21%*)
6 107 (39%, 33–45) 129 (56%*, 49–63) 65 41* 6 (6%) 6 (5%) 89 (83%) 113 (88%) 48 (45%) 50 (39%)
7 106 (37%, 31–42) 160 (60%*, 52–68) 46 18* 6 (6%) 12 (8%) 1 (1%) 1 (1%) 54 (51%) 72 (45%)
8 131 (54%, 47–60) 179 (69%*, 58–80) 40 20* 16 (12%) 27 (15%) 53 (41%) 49 (27%*) 95 (73%) 111 (64%)
9 180 (74%, 69–80) 175 (73%, 68–78) 36 13* 109 (61%) 115 (66%) 58 (32%) 47 (27%) 132 (73%) 134 (77%)
Total** 1,182 (55%, 53–57) 1,448 (63%*, 61–65) 44 22* 239 (23%) 290 (19%*) 650 (62%) 704 (56%*) 693 (62%) 745 (53%*)
*p < 0.05 compared to 2011.
**Weighted for sampling method (note that the reported percentages may not match the percentages obtained by dividing the raw numbers due to
weighting to account for the sampling method).
DR-TB, drug-resistant tuberculosis; PHC, primary health care; SL, second-line; TB, tuberculosis.
doi:10.1371/journal.pmed.1002238.t003
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Univariate analysis of factors associated with second-line treatment
initiation
The percentage of new RR-TB patients initiating second-line treatment was similar across age
groups, with the exception of patients aged 55 y and older (56%, 95% CI 49%–63%), who had a
lower median treatment initiation rate than to patients aged 45–54 y (71%, 95% CI 66%–76%)
(p< 0.001) (Table 5). The median time to treatment was longer for children aged 0–15 y (41 d,
IQR 5–77) compared to individuals aged 16–24 y (21 d, IQR 2–41) (p = 0.04); children were
predominantly treated in hospitals and not in primary care. There was no difference in the
percentage of patients who initiated treatment or time to treatment by sex.
Treatment initiation among HIV-positive patients (67%, 95% CI 65%–70%) was lower than
among HIV-negative patients (83%, 95% CI 79%–86%) (p< 0.001) (Table 5), while there was
a low level of treatment initiation among patients with unknown HIV status (9%, 95% CI 6%–
12%). There was no difference in treatment initiation between HIV-positive patients diag-
nosed with Xpert (67%, 95% CI 64%–70%) compared to those diagnosed with other tests
(67%, 95% CI 63%–71%); however, the median time to treatment was significantly reduced
with Xpert diagnosis (24 d, IQR 2–28, versus 34 d, IQR 10–59) (p< 0.001) (Table 5). Not
unexpectedly, the highest treatment initiation rate was seen among patients diagnosed directly
through TB hospitals (82%, 95% CI 75%–88%). Treatment initiation was lower among patients
diagnosed in either secondary (56%, 95% CI 52%–60%) or tertiary (58%, 95% CI 49%–69%)
hospitals compared to those diagnosed in primary health care facilities (63%, 95% CI 61%–
66%) (p< 0.001) (Table 5).
Discussion
The proportion of diagnosed RR-TB patients initiating second-line treatment in South Africa
improved significantly between 2011 and 2013, increasing from 55% to 63%. However, the
remaining patients, 37% in 2013, represent the treatment gap and are likely to contribute to
ongoing transmission in the community and to suffer from high mortality. This estimate is
higher than reports of initial loss to follow-up among all TB cases in different settings in South
Africa, which range from 11% to 25% in recent studies [8–10], suggesting that there are
Table 4. For previously diagnosed rifampicin-resistant tuberculosis patients, time from first recorded rifampicin-resistant tuberculosis diagnosis,
HIV status, treatment initiation, and time to treatment by previous second-line treatment status (not weighted for sampling method).
Characteristic Previously diagnosed—no previous SL treatment
identified, N = 188
Previously diagnosed—previous SL treatment
identified, N = 197
Median time from first recorded RR-TB
diagnosis (months)
19 (IQR 9–29) Not able to be determined
Smear status
Negative 53 (28%) 62 (32%)
Positive 108 (57%) 66 (34%)
Missing 27 (14%) 69 (65%)
HIV status
Negative 67 (36%) 58 (29%)
Positive 115 (61%) 133 (68%)
Unknown 6 (3%) 6 (3%)
SL treatment start within 6 mo 148 (76%) 19 (9%)
Median time to SL treatment (days) 35 (IQR 6–66) 28 (IQR 0–65)
IQR, interquartile range; RR-TB, rifampicin-resistant tuberculosis; SL, second-line.
doi:10.1371/journal.pmed.1002238.t004
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additional barriers to initiation of second-line treatment for DR-TB. These barriers might be
expected to include high pre-treatment mortality, given long delays to receiving drug suscepti-
bility test results, and more restricted access to second-line treatment, resulting most com-
monly from the need for referral for treatment initiation.
Routine estimates of the treatment gap are derived from aggregate data from different data
sources: diagnosed patients from laboratory reports and treated patients from the national
DR-TB register. The treatment gap of 37% in our 2013 cohort is similar to the 38% of cases not
started on treatment in that year according to the routine reporting system. However, this sim-
ilarity may be coincidental; in the current study only 53% of patients in 2013 who started sec-
ond-line treatment were actually recorded in the national DR-TB treatment register in South
Africa. The remaining 47% were not registered in the treatment register and yet were initiated
on second-line treatment within 6 mo of the diagnostic specimen. This suggests that the esti-
mate of treatment initiation percentage using routine data is flawed. Potentially, this flawed
calculation could be due to inaccurate algorithms for matching duplicate laboratory results
and to long delays in registering patients in the national register, so that registrations reflect
Table 5. Second-line treatment initiation within 6 mo, time to treatment, and site of treatment initiation by age, sex, HIV status, diagnostic facility,
and diagnostic test (new rifampicin-resistant tuberculosis patients, 2013 cohort).
Characteristic N Started SL treatment, N (percent*,
95% CI)
Median time to SL treatment,
days* (IQR)
Started SL treatment in PHC, N
(percent*, 95% CI)
Age (years)
0–15 64 42 (74%, 63–86) 41 (5–77) 1 (2%, 0–6)
16–24 281 191 (66%, 60–71) 21 (2–41) 45 (24%, 18–30)
25–34 734 461 (63%, 60–66) 20 (1–39) 96 (20%, 17–24)
35–44 672 400 (59%, 55–62) 21 (1–42) 79 (17%, 13–21)
45–54 346 243 (71%, 66–76) 28 (9–48) 49 (19%, 14–24)
55+ 204 110 (56%, 49–63) 20 (1–39) 20 (16%, 9–24)
Sex
Female 1,092 675 (61%, 58–63) 23 (1–45) 142 (19%, 16–22)
Male 1,217 773 (65%, 62–67) 21 (4–41) 148 (19%, 16–21)
HIV status
Negative 460 382 (83%, 79–86) 22 (2–42) 7 (24%, 20–29)
Positive 1,517 1,039 (67%, 65–70) 21 (1–42) 88 (17%, 14–19)
Missing 332 27 (9%, 6–12) 36 (0–77) 195 (30%, 11–47)
HIV positive
Diagnosed with Xpert 916 601 (67%, 64–70) 24 (2–28) 123 (18%, 15–21)
Diagnosed by other
method
601 452 (67%, 63–71) 34 (10–59) 72 (15%, 11–18)
Diagnostic facility
type
PHC 1,563 1,013 (63%, 61–66) 22 (2–42) 255 (25%, 22–28)
Secondary hospital 533 283 (56%, 52–60) 24 (0–48) 28 (8%, 5–11)
Tuberculosis hospital 106 88 (82%, 75–88) 6 (0–25) 2 (2%, 1–4)
Tertiary hospital 85 48 (58%, 49–69) 25 (13–38) 4 (8%, 0–15)
Other 22 16 (77%, 54–99) 20 (2–37) 1 (8%, 1–29)
All percentages and times are weighted for sampling method.
*All percentages and times are weighted (note that the reported percentages may not match the percentages obtained by dividing the raw numbers due to
weighting to account for the sampling method).
IQR, interquartile range; PHC, primary health care; SL, second-line.
doi:10.1371/journal.pmed.1002238.t005
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patients diagnosed in previous years. In addition, it could be due to multiple treatment epi-
sodes for individual patients being counted as separate patients in the register. This disconnect
between laboratory-reported notifications and patients initiating treatment points to the need
for an integrated diagnosis and treatment register for programme monitoring.
The low registration rate of treated patients in the national register is concerning in itself,
and likely reflects programmatic issues in the management of the database. In many provinces,
patients can be registered only by staff at centralised facilities, suggesting that patients started
on treatment at lower health system levels may not be registered in the system. This situation
may also have contributed to the drop in the percentage registered between 2011 and 2013. It
is also possible that registration of patient data in the system is severely delayed in many set-
tings, also contributing to the difference between the cohorts. In order to provide effective and
timely feedback, such a registration system should ideally include all diagnosed cases, not just
those treated, and be updated regularly at all treatment initiation sites.
Between 2011 and 2013, South Africa implemented the Xpert MTB/RIF test for all individu-
als being investigated for TB. Universal access to DST is recommended by the World Health
Organization and was expected to substantially increase case detection, given that the majority
of RR-TB cases are among previously untreated TB patients, who were not offered DST under
previous guidelines. Indeed, in South Africa, the annual number of RR-TB cases notified to
WHO increased by more than 80% between 2011 and 2014 [1,11]. In South Africa, the imple-
mentation of Xpert is likely to have contributed substantially to the drop in median time to
treatment between 2011 and 2013. Although there is little empiric evidence, the month prior
to starting TB treatment is likely to represent the time period with the highest level of infec-
tiousness, and, as such, for RR-TB, a gain of close to a month between presentation to a health
facility and starting second-line treatment is likely to contribute to reducing ongoing transmis-
sion [5].
However, diagnosis using the Xpert test did not significantly impact the treatment gap. In
2013, by 6 mo, similar proportions of patients diagnosed with Xpert had initiated second-line
treatment compared to those diagnosed by other methods. These data suggest that the reduc-
tion in the treatment gap between 2011 and 2013 is likely to be due to other programmatic
improvements. In 2011, the South African National Department of Health released a new pol-
icy supporting decentralisation and deinstitutionalisation of DR-TB care [12]. The 2011 policy
allowed for ambulatory treatment of DR-TB through primary care services, and was driven
primarily by a shortage of specialist TB hospital beds and the presence of waiting lists for
admission and therefore treatment initiation [12]. While the extent of decentralised treatment
provision varies across South African provinces, several decentralised RR-TB programmes in
South Africa have demonstrated treatment gaps of less than 10% [13,14], suggesting that
decentralised care can contribute to reducing the treatment gap. While data from the current
study show some improvement in the proportion of RR-TB patients initiating treatment at
lower levels of the health system, 49% still started treatment at tertiary or specialised TB hospi-
tals in 2013, and there was no change in the proportion starting treatment in primary care set-
tings. However, there was substantial variation across South African provinces reflecting
variable implementation of the decentralisation policy [15]. Variations in how the national
decentralisation policy has been interpreted and implemented across provinces, along with
other potential improvements in programme management, such as improved communication
of results and referral systems, may have confounded the impact of Xpert on time to treatment
between 2011 and 2013.
Additionally, the median time to treatment, even among patients diagnosed with Xpert,
was still substantially higher than the 5-d national target [7], although this target may not be
realistic given the need for counselling and pre-treatment testing. Given that the laboratory
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diagnosis was made in a median of 1 d for patients diagnosed with Xpert, most of this delay is
due to other health system factors, likely to include delays in communicating laboratory results
to health care facilities, difficulties in recalling patients, and the need for referral and/or hospi-
tal admission where required. The delays to treatment initiation shown here confirm that
Xpert implementation is insufficient in itself, and needs to be combined with improvements in
accessibility of treatment and delivery of patient-centred services, as demonstrated in some set-
tings [14,16].
While the majority of South African provinces showed improvement in the proportion of
patients initiating treatment within 6 mo of diagnosis between 2011 and 2013, treatment initia-
tion within 6 mo ranged from 53% to 74% in 2013, suggesting large treatment gaps even in the
best performing provinces. Improvements in the median time to treatment were more consis-
tent across provinces; however, treatment delay still ranged between 15 and 36 d across prov-
inces in 2013. Overall, only two provinces showed significant levels of treatment initiation in
primary care.
HIV-positive patients were less likely than HIV-negative patients to initiate treatment.
Given that the median time to treatment was similar by HIV status, and there was no differ-
ence in the proportion diagnosed initially with Xpert, this difference is likely due to higher
mortality among HIV-positive patients. Rapid mortality, preventing appropriate treatment ini-
tiation, was shown earlier in some settings in South Africa [17]. These data highlight the
importance of both earlier presentation for testing and further reductions in treatment delay
among HIV-positive RR-TB patients. Particularly long delays in treatment initiation were
observed among the relatively small proportion of children aged<15 y with RR-TB (<3%).
These children were almost entirely started on treatment in hospital settings, most likely con-
tributing to the treatment delay. Given the paucibacillary nature of TB disease in children,
these patients likely represent a small fraction of the total community RR-TB burden in chil-
dren [18]. Improving case detection among this vulnerable group will likely necessitate greater
responsibility for management in primary care settings.
Although Xpert has lower sensitivity than culture for TB diagnosis [3], the proportion of
RR-TB patients initially diagnosed with Xpert was surprisingly low at 59%. Given that only a
small proportion of patients were diagnosed in districts without Xpert availability, the range in
this proportion across the provinces may be indicative of varied practices in implementation
of Xpert. It may be that Xpert is not being utilised for all presumptive TB patients in some set-
tings, whereas in others, further diagnostic testing of patients with negative Xpert tests may be
inadequate.
Across both the 2011 and 2013 cohorts, approximately 8% of patients were found to have had
previous RR-TB diagnoses. This was despite efforts to preferentially include newly diagnosed
patients by excluding those with previous diagnoses in the 6 mo prior to the diagnostic specimen
and all of those already receiving second-line TB treatment. Given the large treatment gap, this
relatively high proportion is not surprising and represents a group of patients who are reappear-
ing in the health system without adequate treatment. The long duration of time from the first
RR-TB diagnosis that could be located suggests that these patients may well have chronic disease
and are likely to contribute significantly to ongoing transmission in the community.
In this study, we were unable to assess the reasons for non-initiation of second-line treat-
ment, although they likely include early mortality, clinician failure to identify laboratory
results showing RR-TB, inability to locate patients, and lack of options for patients to receive
treatment close to where they reside. Unfortunately, mortality data were inconsistently avail-
able, particularly among patients who did not initiate second-line treatment. Few of these
patients had national identification numbers available with which to verify mortality status
through the national deaths registry in South Africa. Additionally, attempts to directly contact
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patients and/or family members were largely unsuccessful, due to changed or incorrect tele-
phone numbers and insufficiently detailed addresses. As a result, we may have underestimated
treatment initiation in circumstances where patients moved long distances to seek treatment
and where names and dates of birth were recorded incorrectly. However, given the high level
of follow-up among cohort patients, this contribution is likely to be low. Time to treatment
may also have been underestimated as we did not include the time for specimen transport in
our estimate. Finally, it is possible that, due to the longer period between diagnosis and follow-
up for the 2011 cohort compared to the 2013 cohort, more patients who initiated treatment
may have been missed in the 2011 cohort compared to the 2013 cohort.
South Africa has demonstrated global leadership in implementing universal access to DST
through access to Xpert for all presumptive TB patients, contributing to substantially increased
case detection for RR-TB. While a significant treatment gap remained in 2013, given increased
case detection, a larger proportion received second-line treatment, with reduced delays to
treatment initiation. The treatment gap in South Africa is in contrast to global figures, where
the vast majority of the global burden of RR-TB remains undiagnosed [1]. However, the large
burden of diagnosed, but untreated, RR-TB patients should and is acting as a catalyst to drive
strategies to provide effective treatment to all diagnosed patients. The National Department of
Health is currently rolling out plans to appoint one “linkage officer” per district with the aim
of enhancing patient tracing and linkage to appropriate treatment for RR-TB patients [19].
Further health system strengthening will likely be required to fully exploit the benefit of new
technologies for diagnosis of TB and drug resistance.
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